Phio Pharmaceuticals Corp.
PHIO
$1.99
-$0.10-4.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 7,060.00% | -98.48% | |||
| Gross Profit | -7,060.00% | 98.48% | |||
| SG&A Expenses | 25.25% | 43.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.34% | 11.83% | |||
| Operating Income | -23.34% | -11.83% | |||
| Income Before Tax | -22.44% | -8.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.44% | -8.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.44% | -8.79% | |||
| EBIT | -23.34% | -11.83% | |||
| EBITDA | -23.35% | -11.80% | |||
| EPS Basic | -9.98% | 71.28% | |||
| Normalized Basic EPS | -9.97% | 71.27% | |||
| EPS Diluted | -9.98% | 71.28% | |||
| Normalized Diluted EPS | -9.97% | 71.27% | |||
| Average Basic Shares Outstanding | 11.32% | 278.76% | |||
| Average Diluted Shares Outstanding | 11.32% | 278.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||